PTSD Treatment Advances: Medical Marijuana, Trauma‑Focused Therapy and Guided Exposure Show Promise

Recent developments are expanding options for post‑traumatic stress disorder (PTSD). In Pennsylvania and West Virginia, PTSD qualifies for the state medical‑marijuana program, allowing patients to discuss cannabis with certified physicians. Early observational studies suggest cannabis may improve sleep, reduce nightmares and lower anxiety, though high‑quality clinical trials have not yet confirmed consistent benefits.

A large Lancet Psychiatry study led by King’s College London, called the STAR trial, found that trauma‑focused cognitive‑behavioral therapy combined with psychosis treatment significantly reduced PTSD symptoms in 305 participants with co‑occurring psychosis. Half of the participants no longer met PTSD criteria after treatment, marking a shift from previous exclusion of this population.

Additional clinical research highlights specialized exposure therapies that guide patients through traumatic memories in a paced, controlled manner—sometimes using “guided walks.” These approaches aim to diminish avoidance behavior and promote neural habituation, offering an alternative for patients who do not respond adequately to medication alone.